Enterprise Innovation

Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

News

Galvanizing Blood Vessel Cells to Expand for Organ Transplantation

October 14, 2025

Scientists have discovered a method to induce human endothelial cells from a small biopsy sample to multiply in the laboratory, producing more than enough cells to replace damaged...
NIH Grant Funds Effort to Target the Root of HIV Persistence

August 15, 2025

A multi-institutional team led by Weill Cornell Medicine has received a five-year, $14.9 million grant from the National Institute of Allergy and Infectious Diseases, part of the...
New Insights into Bladder Cancer Treatment Could Help Improve Immunotherapies

May 29, 2025

Researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center are expanding the understanding of how the BCG treatment for early bladder cancer works.